Table 2 Correlation between pMEK5 expression and clinicopathologic characteristics
From: Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer
Variable | Cases | pMEK5 protein | Pvalue | |
|---|---|---|---|---|
| Â | Â | Normal expression | Overexpression | Â |
Sex | Â | Â | Â | 0.055 |
   Female | 158 | 79(50.0%) | 79(50.0%) |  |
   Male | 177 | 70(39.5%) | 107(60.5%) |  |
Age at surgery, years | Â | Â | Â | 0.835 |
   < 65 | 189 | 85(45.0%) | 104(55.0%) |  |
   ≥ 65 | 146 | 64(43.8%) | 82(56.2%) |  |
Tumour location | Â | Â | Â | 0.440 |
   Right colon | 57 | 21(36.8%) | 36(63.2%) |  |
   Left colon | 99 | 45(44.5%) | 54(54.5%) |  |
   Rectum | 179 | 83(46.4%) | 96(53.6%) |  |
pT (invasion depth) | Â | Â | Â | 0.001 |
   T1+ T2 | 62 | 39(62.9%) | 23(37.1%) |  |
   T3+ T4 | 273 | 110(40.3%) | 163(59.7%) |  |
pN (lymph node metastasis) | Â | Â | Â | < 0.001 |
   N0 | 203 | 113(55.7%) | 90(44.3%) |  |
   N1-N2 | 132 | 36(27.3%) | 96(72.7%) |  |
pM (distant metastasis) | Â | Â | Â | < 0.001 |
   M0 | 305 | 146(47.9%) | 159(52.1%) |  |
   M1 | 30 | 3(10.0%) | 27(90.0%) |  |
TNM stage | Â | Â | Â | < 0.001 |
   I | 49 | 35(71.4%) | 14(28.6%) |  |
   II | 145 | 78(53.8%) | 67(46.2%) |  |
   III | 111 | 33(29.7%) | 78(70.3%) |  |
   IV | 30 | 3(10.0%) | 27(90.0%) |  |
Differentiation grade | Â | Â | Â | 0.074 |
   Well | 29 | 17(58.6%) | 12(41.4%) |  |
   Moderate | 278 | 124(44.6%) | 154(55.4%) |  |
   Poorly | 28 | 8(28.6%) | 20(71.4%) |  |
Preoperative CEA level | Â | Â | Â | < 0.001 |
   < 5 ng/ml | 190 | 102(53.7%) | 88(46.3%) |  |
   ≥ 5 ng/ml | 145 | 47(32.4%) | 98(67.6%) |  |
Preoperative CA19-9 level | Â | Â | Â | 0.251 |
   < 60 U/ml | 296 | 135(45.6%) | 161(54.4%) |  |
   ≥ 60 U/ml | 39 | 14(35.9%) | 25(64.1%) |  |